What do systematic reviews say?

Lesinurad 400 mg plus febuxostat CONTINUED vs lesinurad 200 mg plus febuxostat CONTINUED

Lesinurad 400 mg plus febuxostat CONTINUED showed no clear difference in proportion with complete resolution of a target tophus compared with lesinurad 200 mg plus febuxostat CONTINUED (low certainty).

• Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
  RR 1.11 [0.85, 1.46]
  1 study · 129 participants
  Low

Lesinurad 400 mg plus febuxostat CONTINUED vs lesinurad 200 mg plus febuxostat CONTINUED

Lesinurad 400 mg plus febuxostat CONTINUED showed no clear difference in total adverse events compared with lesinurad 200 mg plus febuxostat CONTINUED (low certainty).

• Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
  RR 1.12 [0.96, 1.32]
  1 study · 129 participants
  Low

Lesinurad 400 mg plus febuxostat CONTINUED vs lesinurad 200 mg plus febuxostat CONTINUED

Lesinurad 400 mg plus febuxostat CONTINUED showed no clear difference in number of participant withdrawals due to adverse events compared with lesinurad 200 mg plus febuxostat CONTINUED (low certainty).

• Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
  RR 0.98 [0.44, 2.2]
  1 study · 129 participants
  Low

Lesinurad 400 mg plus febuxostat CONTINUED vs lesinurad 200 mg plus febuxostat CONTINUED

• Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 129 participants
  Low